Extended-Release Formulations of Safer Opioids: Improving Adherence and Reducing Mental Health Burdens
Article Information
Publication Timeline
- Received08 January 2022
- Accepted01 February 2022
Abstract
The opioid crisis remains a significant public health challenge, with opioid misuse, dependence, and mental health comorbidities posing serious concerns for patients and healthcare providers alike. Extended-release (ER) formulations of opioids have been developed as a means to provide stable analgesia while mitigating risks associated with immediate-release (IR) formulations. This paper critically examines how ER formulations of safer opioids can enhance medication adherence, reduce withdrawal symptoms, minimize abuse potential, and lower the mental health burdens associated with opioid use and misuse. The analysis is based exclusively on research findings published, ensuring a historical perspective on the evolution of ER opioid formulations and their clinical implications.
Keywords
Extended-release opioidsopioid adherenceabuse-deterrent formulationsopioid crisismental healthpain managementopioid misusepharmacokineticsReferences
- Almehlisi A, Tainter C. Emergency Medicine Practice. 2019;21(11):1–24. [Google Scholar][Crossref]
- Anderson D, Zlateva I, Khatri K, Ciaburri N. Using health information technology to improve adherence to opioid prescribing guidelines in primary care. The Clinical Journal of Pain. 2015;31(6):573–579. [Google Scholar][Crossref]
- Bershad AK, Ruiz NA, De WH. Effects of buprenorphine on responses to emotional stimuli in individuals with a range of mood symptomatology. International Journal of Neuropsychopharmacology. 2018;21(2):120–127. [Google Scholar][Crossref]
- Bohnert ASB, Ilgen MA. Understanding links among opioid use, overdose, and suicide. The New England Journal of Medicine. 2019;380(1):71–79. [Google Scholar][Crossref]
- Brady KT, McCauley JL, Back SE. Prescription opioid misuse, abuse, and treatment in the United States: An update. The American Journal of Psychiatry. 2016;173(1):18–26. [Google Scholar][Crossref]
- Bruera E, Paice JA. Cancer pain management: safe and effective use of opioids. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting. 2015:e593–9. [Google Scholar][Crossref]
- Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. The Journal of Pain: Official Journal of the American Pain Society. 2013;14(4):351–358. [Google Scholar][Crossref]
- Candiotti KA, Gitlin MC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Current Medical Research and Opinion. 2010;26(7):1677–1684. [Google Scholar][Crossref]
- Carey M, Gospin R, Goyal A, et al. Opioid receptor activation impairs hypoglycemic counterregulation in humans. Diabetes. 2017;66(11):2764–2773. [Google Scholar][Crossref]
- Cepeda MS, Fife D, Ma Q, Ryan PB. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. The Journal of Pain: Official Journal of the American Pain Society. 2013;14(10):1227–1241. [Google Scholar][Crossref]
- Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Annals of Internal Medicine. 2015;162(4):276–286. [Google Scholar][Crossref]
- Devulder J, Jacobs A, Richarz U, Wiggett H. Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain. British Journal of Anaesthesia. 2009;103(4):576–585. [Google Scholar][Crossref]
- Dripps IJ, Jutkiewicz EM. Delta opioid receptors and modulation of mood and emotion. Handbook of Experimental Pharmacology. 2018;247:179–197. [Google Scholar][Crossref]
- Edlund MJ, Martin BC, Russo JE, et al. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: The role of opioid prescription. The Clinical Journal of Pain. 2014;30(7):557–564. [Google Scholar][Crossref]
- Gatti A, Gentili M, Baciarello M, et al. Breakthrough pain in patients with controlled or uncontrolled basal pain: an observational study. Journal de la Societe Canadienne pour le Traitement de la Douleur [Pain Research & Management]. 2014;19(6):e168–71. [Google Scholar][Crossref]
- George B, Minello C, Allano G, et al. Opioids in cancer-related pain: current situation and outlook. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2019;27(8):3105–3118. [Google Scholar][Crossref]
- Hooten WM, Bruce BK. Beliefs and attitudes about prescribing opioids among healthcare providers seeking continuing medical education. Journal of Opioid Management. 2011;7(6):417–424. [Google Scholar][Crossref]
- Hwang CS, Kang EM, Ding Y, et al. Patterns of immediate-release and extended-release opioid analgesic use in the management of chronic pain, 2003– 2014. JAMA Network Open. 2018;1(2):e180216. [Google Scholar][Crossref]
- Iwanicki JL, Severtson SG, McDaniel H, et al. Abuse and diversion of immediate-release opioid analgesics as compared to extended-release formulations in the United States. PLOS ONE. 2016;11(12):e0167499. [Google Scholar][Crossref]
- Jones MR, Carney MJ, Kaye RJ, et al. Drug formulation advances in extended-release medications for pain control. Current Pain and Headache Reports. 2016;20(6):36. [Google Scholar][Crossref]
- Kopecky EA, Fleming AB, Levy-Cooperman N, et al. Oral human abuse potential of oxycodone DETERx® (Xtampza® ER). Journal of Clinical Pharmacology. 2017;57(4):500–512. [Google Scholar][Crossref]
- Kosten TR, Baxter LE. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. The American Journal on Addictions. 2019;28(2):55–62. [Google Scholar][Crossref]
- Manchikanti L, Helm S, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3 International Journal of Medical and All Body Health Research www.allmedicaljournal.com Suppl):ES9–38. [Google Scholar][Crossref]
- Martin C, De Baerdemaeker A, Poelaert J, et al. Controlled-release of opioids for improved pain management. Materials Today (Kidlington, England). 2016;19(9):491–502. [Google Scholar][Crossref]
- Mayock SP, Saim S, Fleming AB. In vitro drug release after crushing: Evaluation of Xtampza® ER and other ER opioid formulations. Clinical Drug Investigation. 2017;37(12):1117–1124. [Google Scholar][Crossref]
- McLane VD, Bergquist I, Cormier J, Barlow DJ, Houseknecht KL, Bilsky EJ, Cao L. Long-term morphine delivery via slow release morphine pellets or osmotic pumps: Plasma concentration, analgesia, and naloxone-precipitated withdrawal. Life Sciences. 2017;185:1–7. [Google Scholar][Crossref]
- Morton TL, Devarakonda K, Kostenbader K, Montgomery J, Barrett T, Webster L. Correlation of subjective effects with systemic opioid exposure from fixed-dose combinations of oxycodone/acetaminophen in recreational users of prescription drugs. Pain Medicine. 2016;17(3):539–550. [Google Scholar][Crossref]
- Paul SM, Allread V. Opioid misuse, abuse and addiction part 2: Opioid prescriber responsibilities and resources. MD Advisor: A Journal for the New Jersey Medical Community. 2017;10(1):4–16. [Google Scholar][Crossref]
- Pendergrass SA, Crist RC, Jones LK, Hoch JR, Berrettini WH. The importance of buprenorphine research in the opioid crisis. Molecular Psychiatry. 2019;24(5):626– 632. [Google Scholar][Crossref]
- Pergolizzi JV Jr, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. Journal of Clinical Pharmacy and Therapeutics. 2020;45(5):892–903. [Google Scholar][Crossref]
- Pergolizzi JV, Raffa RB, Pergolizzi JS, Taylor R. Non-analgesic effects of opioids: Factors relevant to opioid abuse and abuse-deterrent formulations. Current Pharmaceutical Design. 2012;18(37):6109–6115. [Google Scholar][Crossref]
- Rauck RL. Mitigation of IV abuse through the use of abuse-deterrent opioid formulations: An overview of current technologies. Pain Practice: The Official Journal of World Institute of Pain. 2019;19(4):443–454. [Google Scholar][Crossref]
- Rogers AH, Zvolensky MJ, Ditre JW, Buckner JD, Asmundson GJG. Association of opioid misuse with anxiety and depression: A systematic review of the literature. Clinical Psychology Review. 2021;84(101978):101978. [Google Scholar][Crossref]
- Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, Marshall BDL, Tyndall M, Walsh SL. Opioid use disorder. Nature Reviews. Disease Primers. 2020;6(1):3. [Google Scholar][Crossref]
- Vadivelu N, Schermer E, Kodumudi G, Berger JM. The clinical applications of extended-release abuse-deterrent opioids. CNS Drugs. 2016;30(7):637–646. [Google Scholar][Crossref]
- Webster LR, Markman J, Cone EJ, Niebler G. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgraduate Medicine. 2017;129(1):102–110. [Google Scholar][Crossref]
- Yu S, Shen W, Yu L, Hou Y, Han J, Richards HM. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: A phase 3, randomized, double-blind, multicenter study. The Journal of Pain: Official Journal of the American Pain Society. 2014;15(8):835–844. [Google Scholar][Crossref]
How to Cite
Ameh, S., Asogwa, K., Awojulu, T., Oturu, O., & Ezeani, J. (2022). Extended-Release Formulations of Safer Opioids: Improving Adherence and Reducing Mental Health Burdens. International Journal of Medical and All Body Health Research, 3(1), 83-86. https://doi.org/10.54660/IJMBHR.2022.3.1.83-86
Ameh, Sunday, et al. "Extended-Release Formulations of Safer Opioids: Improving Adherence and Reducing Mental Health Burdens." International Journal of Medical and All Body Health Research, vol. 3, no. 1, 2022, pp. 83-86. https://doi.org/10.54660/IJMBHR.2022.3.1.83-86.
Ameh, S., Asogwa, K., Awojulu, T., Oturu, O. and Ezeani, J. (2022) 'Extended-Release Formulations of Safer Opioids: Improving Adherence and Reducing Mental Health Burdens', International Journal of Medical and All Body Health Research, 3(1), pp. 83-86. doi: 10.54660/IJMBHR.2022.3.1.83-86.
Ameh S, Asogwa K, Awojulu T, Oturu O, Ezeani J. Extended-Release Formulations of Safer Opioids: Improving Adherence and Reducing Mental Health Burdens. International Journal of Medical and All Body Health Research. 2022;3(1):83-86. doi:10.54660/IJMBHR.2022.3.1.83-86
Similar Articles
- Enhancing biopharmaceutical supply chains: Strategies for efficient drug formulary development in emerging markets Vol 3, Issue 1 (2022)
- Novel phytochemicals in traditional medicine: Isolation and pharmacological profiling of bioactive compounds Vol 3, Issue 1 (2022)
- Pregnancy outcome in women with epilepsy: A pilot study in Oman Vol 3, Issue 1 (2022)
- Significant role of nanotechnology in cancer and molecular genetics: An overview Vol 3, Issue 1 (2022)
- Accessibility evaluation of physically disable persons at government hospitals in Peshawar, Pakistan Vol 3, Issue 1 (2022)
Find this Article on
Google Scholar Semantic Scholar OpenAlex Scilit Crossref ResearchGate BASEA newly published article may take a few days to appear on these services.